Medical

An unnamed angel investment group is providing up to $3.5 million dollars to St. Renatus for Phase 3 clinical trials of its nasal mist dental anesthesia. St. Renatus announced in March 2011 that it had had a successful end-of-Phase 2 meeting with FDA regulators and planned to move ahead with Phase 3. The product, delivered to the nasal cavity, numbs only the upper … [Read more...] about St Renatus gets funding for Phase 3 development of nasal spray dental anesthesia

According to Pearl Therapeutics, it has completed two Phase 2b clinical studies of PT003, its inhaled combination bronchodilator for the treatment of moderate-to-severe COPD, and is "on-track to commence Phase 3 program in 2012." One of the trials was a dose confirmation study of various doses of PT003 compared to its components, PT001 and PT005; the other was a … [Read more...] about Pearl ready to begin Phase 3 studies of PT003

Civitas Therapeutics has announced positive results from a Phase 1 clinical study of its CVT-301 inhaled dry powder formulation of levodopa (L-dopa) for the treatment of Parkinson’s disease. According to the company, the study showed that all of the doses tested were well tolerated, and sufficient plasma levels of L-dopa were achieved in healthy volunteers who inhaled … [Read more...] about Positive Phase 1 results for inhaled L-dopa

ISTA Pharmaceuticals says that it has initiated a Phase 2 study of its Beposone bepotastine besilate/steroid combination nasal spray for the treatment of seasonal allergic rhinitis. Approximately 600 patients with allergic rhinitis caused by mountain cedar pollen are expected to take part in the randomized, placebo-controlled, parallel-group environmental study, which … [Read more...] about Phase 2 study of ISTA’s bepotastine-steroid nasal spray begins

Pulmatrix has presented data at the 11th US-Japan Symposium on Drug Delivery Systems in Hawaii that it says demonstrate the superiority of its iSPERSE inhalation platform over lactose formulations for combination dry powder inhalers. The iSPERSE technology makes use of a "delivery matrix containing proprietary cationic salt formulations" that allows for increased … [Read more...] about Pulmatrix says iSperse data show superiority over lactose blends for DPIs

An article published in the December 8, 2011 issue of the New England Journal of Medicine describes a proof of principle study in which an intranasal dry powder vaccine significantly reduced Norwalk virus gastroenteritis and infection in study participants innoculated with Norwalk virus. LigoCyte Pharmaceuticals created the vaccine from virus-like particles since … [Read more...] about Intranasal norovirus vaccine capable of reducing infection

Pearl Therapeutics has announced positive top-line results from a Phase 2b dose-ranging study of its PT001 glycopyrrolate (GP) MDI in patients with moderate-to-severe COPD. The randomized, double-blind study compared 4 doses of the PT001 MDI to placebo and to Atrovent HFA inhalation aerosol. According to Pearl all of the doses of GP tested demonstrated statistically … [Read more...] about Positive Phase 2b results for Pearl’s PT001